Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma
Interventions: Nintedanib, Bevacizumab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cervical Cancer, Precancerous Condition
Interventions: Fenretinide, Placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Interventions: Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed; Biological · Drug
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 20
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Head and Neck Carcinoma
Interventions: Medical Chart Review, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Carcinoma
Interventions: Bioelectric Impedance Analysis, Computed Tomography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Procedure · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thoracic Neoplasms, Lung Neoplasms, Esophagus Neoplasms, Pleural Neoplasms, Thymus Neoplasms
Interventions: TOGA Tools; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 70 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Head and Neck Cancer
Interventions: carboplatin, cisplatin, docetaxel, fluorouracil; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 14
States / cities: La Jolla, California • Denver, Colorado • Boca Raton, Florida + 11 more

Conditions: Oropharynx Cancer
Interventions: Gabapentin, Placebo Oral Capsule; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cervical Intraepithelial Neoplasia
Interventions: E7 TCR; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer, Pulmonary Disease, Chronic Obstructive
Interventions: LIFE Bronchoscopy; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 85 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Spinal Deformity, Spinal Infection, Trauma, Neoplastic Processes, Degenerative Spinal Conditions
Interventions: Pedicle screw instrumentation using Mazor X robotic system; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Esophageal Cancer
Interventions: sunitinib malate; Drug
Lead sponsor: Tony Bekaii-Saab; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Esophageal Neoplasms
Interventions: Capecitabine (Xeloda); Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions: ²¹²Pb-DOTAM-GRPR1; Drug
Lead sponsor: Orano Med Theranostics, SAS; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 8
States / cities: Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more

Conditions: Oral Mucositis
Interventions: ALD518, 0.9% saline; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more

Conditions: Thyroid Cancer
Interventions: sorafenib with everolimus; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more

Conditions: Head and Neck Cancer, Head and Neck Trauma
Interventions: RECELL® Autologous Cell Harvesting Device; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Guilford, Connecticut • Milford, Connecticut • New Haven, Connecticut

Conditions: Head and Neck Cancer
Interventions: Not listed
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Head and Neck Cancer
Interventions: cetuximab, bortezomib, cisplatin, intensity-modulated radiation therapy; Biological · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 2
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Nivolimumab+Carboplatin/paclitaxel+Radiation; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • New York, New York + 1 more

Conditions: Salivary Gland Squamous Cell Carcinoma, Stage II Salivary Gland Cancer, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: intensity-modulated radiation therapy, cisplatin, image-guided adaptive radiation therapy, 3'-deoxy-3'-[18F]fluorothymidine, positron emission tomography/computed tomography, fludeoxyglucose F 18; Radiation · Drug · Other + 1 more
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 19 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Xerostomia
Interventions: sugar-free chewing gum, chewing gum, mouth rinse, mouth spray; Other · Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 13 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Solid Tumor
Interventions: SB 11285, Atezolizumab; Drug
Lead sponsor: invoX Pharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Oropharyngeal Cancer, Squamous Cell Carcinoma to the Head and Neck
Interventions: Lyrica 300 mg, Placebo; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Fenretinide in Treating Patients With Cervical Neoplasia

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Medical Data Collection of Patients With Head and Neck Cancer Treated With Proton Therapy

Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy

Thoracic OncoGeriatric Assessment (TOGA) Trials

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)

Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer

Analysis of Pedicle Screw Accuracy to Plan Using Medtronic Mazor Robotic System

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

Skin Color Matching in Head and Neck Reconstructive Surgery

Medical Cannabis During Chemoradiation for Head and Neck Cancer

Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC

Comparing Over-the-counter Dry Mouth Remedies After Radiation

Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.